Key facts
- Numenos’s last known valuation is $21.8M (Jan 2025).
- It has raised $7.7M; the latest was Seed Round ($7.7M) in Jan 2025.
- Notable investors include Dhuna Ventures, Meron Capital, TechAviv Founder Partners.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Numenos
- ·The full record, as it builds
Funding rounds
No funding rounds for Numenos are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Numenos
Developer of an artificial intelligence clinical trial development platform designed to uncover new biology and biomarkers that predict patient response. The company's platform specializes in detecting biomarkers early in clinical trial development, facilitating cheaper and more successful phase-III clinical trial design, enabling healthcare sector to reduce the cost and time of clinical trials.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2023
- Employees
- 14
- Website
- numenos.ai/
- Ownership
- Privately Held (backing)
Numenos doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Numenos shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Numenos in its N-PORT filings yet. We sweep new filings monthly.